Morana Jovan-Embiricos
CIK 1575745 · last filed 2026-06-04
Morana Jovan-Embiricos is a corporate insider who has filed 23 SEC Form 4 insider transactions across 5 companies since 2014. The most recent filing, for KLRS, was dated Jun 4, 2026. Across all open-market trades the lifetime net is +$43.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $6.9M across reported positions. 8 SEC filings were submitted jointly with F2 MG Ltd.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALVR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
201 BROADWAY, 6TH FLOOR
BOSTON, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KLRS | Director | — | $2.38 | — | $0 | 2 | 2026-06-04 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | Director | 42,081 | $9.81 | $412.8K | $48.59M | 11 | 2024-06-07 |
| CGEM | Director | 578,214 | $12.01 | $6.94M | -$5.35M | 4 | 2022-06-28 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | 10%+ Owner | 392,185 | $1.48 | $580.4K | -$58.9K | 1 | 2019-10-24 |
| Radius Health, Inc. (RDUS) Delisted | Director | 0 | $30.00 | $0 | $0 | 5 | 2015-01-20 |
Recent Filings
23 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-04 | KLRS | Grant (A) | — | $0 | EDGAR |
| 2025-04-11 | KLRS | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +35,000 | $0 | EDGAR |
| 2023-05-12 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +35,000 | $0 | EDGAR |
| 2022-08-01 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +8,152,247 | $37.58M | EDGAR |
| 2022-06-28 | CGEM | Mixed | +95,296 | $14 | EDGAR |
| 2022-06-23 | CGEM | Sell (S) | −101,903 | -$1.30M | EDGAR |
| 2022-05-19 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-16 | CGEM | Sell (S) | −418,738 | -$4.05M | EDGAR |
| 2022-03-25 | CGEM | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.